Drugs / CMV-VST
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT07015801 | Apr 2025 → Apr 2027 expected | T-cell immunodeficiency, cytomegalovirus pneumonia | University of Calgary | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CMV-VST | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07015801 ↗ |
| Modality | Cell therapy | “a cell therapy product containing a mixture of donor lymphocytes” NCT07015801 ↗ |